• Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of morning joint stiffness in moderate to severe rheumatoid arthritis (RA) patients.

• Discovered by Incyte Corporation (NASDAQ: INCY) and licensed to Lilly, Olumiant is an oral Janus kinase (JAK) inhibitor approved for treating moderately to severely active RA in adults.

• Trial data showed that Olumiant also enhanced overall physical function at 12 weeks compared to adalimumab and placebo.

• The changes in pain relief were not affected by disease activity during treatment, Lilly noted.

• Furthermore, subjects receiving Olumiant had greater improvements in fatigue versus placebo, and the improvements were comparable to AbbVie Inc's (NYSE: ABBV) Humira after 12 weeks.

• Price Action: LLY shares are up 0.47% at $199.35 during the market session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Almost Half of Crohn's Disease Patients Achieved Endoscopic Response After One Year of Maintenance Treatment with AbbVie's Risankizumab

• AbbVie's Rinvoq Shows Encouraging Long Term Safety, Efficacy In Rheumatoid Arthritis, Psoriatic Arthritis Patients

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.